
    
      This was a 10-year study which had an initial 52-week, double-blind, placebo-controlled phase
      followed by an open-label extension phase up to 9 years in duration. Data were analyzed for
      the double-blind phase using all patients who were randomized and received at least one dose
      of study drug through Week 52 and for all patients who received at least one dose of
      adalimumab during the 10-year study (the Intent-to-Treat [ITT] population).
    
  